Table 1 Clinical characteristics of LUAD and LUSC cohorts
From: Spatially mapping the tumour immune microenvironments of non-small cell lung cancer
LUAD (n, %) | LUSC (n, %) | |
|---|---|---|
Sex | ||
Female | 23 (45.1%) | 18 (35.3%) |
Male | 28 (54.9%) | 33 (64.7%) |
Age (years) | ||
<75 | 34 (66.7%) | 34 (66.7%) |
≥75 | 17 (33.3%) | 17 (33.3%) |
BMI (kg/m2) | ||
<30 | 35 (68.6%) | 37 (72.5%) |
≥30 | 16 (31.4%) | 14 (27.5%) |
Smoking status | ||
Smoker | 41 (80.4%) | 47 (92.2%) |
Non-smoker | 10 (19.6%) | 4 (7.8%) |
Pack years | ||
1–30 | 11 (21.6%) | 11 (21.6%) |
≥30 | 27 (52.9%) | 26 (51.0%) |
NA | 13 (25.5%) | 14 (27.4%) |
Stage | ||
I-II | 48 (94.1%) | 43 (84.3%) |
III | 3 (5.9%) | 8 (15.7%) |
Progression | ||
Yes | 14 (27.5%) | 12 (23.5%) |
Death | ||
Yes | 15 (29.4%) | 14 (27.5%) |
Follow-up time | ||
Median, years | 5.59 | 4.22 |
